SLC9A5

Across TCGA cell cohorts, SLC9A5 mutation is significantly associated with the drug of many other genes, with 25 significant associations in total. LARGE_INTESTINE shows the largest number of these associations.

The most reproducible SLC9A5-associated genes across cancer lineages are JNK Inhibitor VIII, Niraparib, and Pevonedistat. Each is linked with SLC9A5 in more than 1 cancer types. Because this analysis shows association rather than direction, both SLC9A5-to-partner and partner-to-SLC9A5 results are reported.

Each partner links to its own Q-omics profile. The box plot shows the strongest example, JNK Inhibitor VIII grouped by SLC9A5-low versus SLC9A5-high in LARGE_INTESTINE.

mutation associated genes by consensus

Ranked by combined sampling and lineage consensus. X-score (SLC9A5→partner) and Y-score (partner→SLC9A5) are standardized regression coefficients; both directions are reported because the association is undirected. p-values are from the association test.

Lineage	Partner gene	X-score	Y-score	p(X)	p(Y)	Sampling consensus	Lineage consensus
LARGE_INTESTINE	JNK Inhibitor VIII →	+0.258	+2.807	.049	.046	3	1
LARGE_INTESTINE	Niraparib →	+0.442	+3.061	.005	.010	3	1
LARGE_INTESTINE	Pevonedistat →	+0.859	+2.871	.007	.021	3	1
LARGE_INTESTINE	CP466722 →	+0.430	+3.067	.015	.009	3	1
LARGE_INTESTINE	Savolitinib →	+0.368	+3.000	.030	.017	3	1
LARGE_INTESTINE	N25720-51-A1 →	+0.474	+2.655	.017	.044	3	1

Each partner links to its Q-omics profile. Showing the 6 strongest of 25 associations by consensus.

JNK Inhibitor VIII by SLC9A5 expression — LARGE_INTESTINE

Explore this box plot interactively →